Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in
Pharmacopedia is being built in public. Pages may be incomplete.About this site

Choose a table:


Medicines > classes : Cathinone or Dual orexin receptor antagonist (DORA)

Use the filters below to narrow your results.

generic:
None (3) · 3-MMC (1) · Butylone (1) · Cathinone (1) · Ephylone (1) · Ethcathinone (1) · Ethylone (1) · Hexedrone (1) · Mephedrone (1) · Methcathinone (1) · Methylone (1) · Mexedrone (1) · N-Ethylhexedrone (1) · N-Ethylpentedrone (1) · Pentedrone (1)
brand:
None (14) · Belsomra (1) · Dayvigo (1) · Quviviq (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · Cathinone analogue; monoamine reuptake inhibitor (2) · Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. (1) · Monoamine releasing agent (4) · Monoamine releasing agent; active ingredient in khat (1) · Norepinephrine and dopamine releasing agent (1) · Norepinephrine/dopamine releasing agent (1) · Norepinephrine/dopamine reuptake inhibitor (1) · Serotonin releasing agent; monoamine reuptake inhibitor (1) · Serotonin/norepinephrine/dopamine releasing agent (3)
uses:
None (14) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1) · Insomnia (sleep onset and/or sleep maintenance) in adults (FDA-approved Jan 2022) (1)
starting dose:
None (14) · 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) (1) · 25 mg PO at bedtime (no titration); may increase to 50 mg if 25 mg inadequate (1) · 5 mg PO at bedtime; may increase to 10 mg if inadequate (1)
preparations:
None (14) · 25 mg, 50 mg tablets (1) · 5 mg, 10 mg tablets (1) · 5 mg, 10 mg, 15 mg, 20 mg tablets (1)
fda max:
None (14) · 10 mg/d (1) · 20 mg/d (1) · 50 mg/d (1)
routes:
None (14) · Oral (3)
onset:
None (14) · ~30 min (3)
duration:
None (14) · ~7-8 hours (3)
halflife:
None (14) · ~12 hours (1) · ~17-19 hours (longer than daridorexant) (1) · ~8 hours (shorter than suvorexant and lemborexant) (1)
bioavailability:
None (14) · ~44% (1) · ~62% (1) · ~82% (1)
pregnancy:
None (14) · Limited data; avoid (3)
legal:
None (14) · Rx, Schedule IV (US) (3)

Showing below up to 17 results in range #1 to #17.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"